Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$27.37 USD

27.37
1,971,701

+0.78 (2.93%)

Updated Oct 10, 2024 04:00 PM ET

After-Market: $27.36 -0.01 (-0.04%) 6:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Bayer (BAYRY) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 3.

Trevena (TRVN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.

Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.

Alkermes (ALKS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote

by Zacks Equity Research

Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.

LGND or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. ALKS: Which Stock Is the Better Value Option?

LGND or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. ALKS: Which Stock Is the Better Value Option?

Why Is Alkermes (ALKS) Down 12% Since Last Earnings Report?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors

by Zacks Equity Research

Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.

ANIK or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.

Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 700.00% and 3.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines (VBIV) to Report Q2 Earnings: What's in Store

by Zacks Equity Research

VBI Vaccine (VBIV) will provide financial updates when it releases second-quarter 2020 results.

ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

Why Alkermes (ALKS) Might Surprise This Earnings Season

by Zacks Equity Research

Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Axcella (AXLA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Axcella AXLA) will provide updates on its clinical programs when it releases second-quarter 2020 results.

Soleno (SLNO) to report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.

Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) will provide financial and corporate updates when it releases second-quarter 2020 results on Jul 30.

BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.

Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.

Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.

Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.